Page 232 - Mployee Wellness Programs News Today

As the industry strives for data use that is standardized, consistent, and fluid, payers that automate data flow, in the long run, will be able to discern the risk of each member and prioritize their needs to drive member services for outcomes-based care delivery.

Opioids are our most effective tool for treating pain, but what if there were a better way to stop pain without relying on addictive substances? To develop a non-addictive painkiller, scientists have been searching for proteins that appear on pain neurons but not in the reward pathway, and this has been no small task.

The United States’ response to addiction and substance use disorders is a criminal justice response and not a public health response — but it shouldn’t be that way, one expert said at Engage at HLTH.

Big Tech companies like Amazon, Google and IBM can’t disrupt healthcare with the same approach they have used to enter other industries, HCA Healthcare CEO Sam Hazen said at HLTH 2022. He argued that technology companies won't be able to infiltrate healthcare from afar. Instead, they must embed themselves into everyday healthcare interactions at hospitals in order for their products and services to be truly impactful.

Manual processes and inadequate analytics frequently prevent hospitals from achieving OR revenue and utilization goals. By using automation, behavioral science, and comprehensive real-world data, hospitals can unleash the full potential of their OR enterprises and supercharge perioperative growth.

Cloud-based data management solutions help the industry meet its business and compliance challenges. These platforms need to replace traditional data management methods and workflows for biopharma companies and contract development and manufacturing organizations that seek competitive advantages.

Phone calls account for 70% of people's first point of contact with a health system, so hospitals have sought to implement software that balances the need for speedy automation with intelligent systems that anticipate and best serve patient and care giver needs.

There are three major tensions that still need to be addressed in virtual care or telemedicine before it can work as promised. Convenient

FDA approval of AstraZeneca’s Imjudo comes less than three weeks after the antibody won its first approval in liver cancer. Both regulatory decisions cover use of the drug in combination with another AstraZeneca immunotherapy, Imfinzi.

While telehealth has provided many benefits throughout the pandemic, it can be a lonely and sterile way of receiving treatment. Individuals experiencing substance use disorder who only receive treatment through telehealth may miss opportunities to connect with others in support of the recovery process.